Scholar Rock Holding Corp 8K

Scholar Rock reported Q2 2026 results, detailed progress of its apitegromab regulatory and clinical programs, initiated an FSHD Phase 2 trial, and highlighted a strong cash position and readiness for potential SMA launch pending FDA approval by the September 30, 2026 PDUFA date.

On August 6, 2026, Scholar Rock Holding Corporation reported its second quarter 2026 financial results and provided a business update, highlighting continued FDA review of its Biologics License Application for apitegromab for spinal muscular atrophy with a September 30, 2026 PDUFA date and two independent fill‑finish facilities under review, active engagement with the EMA on the related Marketing Authorisation Application, initiation of the Phase 2 FORGE trial in facioscapulohumeral muscular dystrophy, ongoing Phase 2 OPAL and Phase 1 SRK‑439 studies, and a strong liquidity position with $492 million in cash, cash equivalents, and marketable securities, including proceeds from its at‑the‑market equity program, alongside a quarterly net loss of $109.9 million and preparations for a potential U.S. commercial launch of apitegromab upon approval.

Filing Facts

CIK

1727196

Ticker

SRRK

Form

8K

Source Type

fda

Accession

0001193125-26-336715

Alert Tier

6